每周一次IcoSema对比每周一次icodec治疗2型糖尿病(COMBINE 1):一项开放标签、多中心、达标治疗、随机、3a期试验
COMBINE 1是一项52周、开放标签、多中心、达标治疗、随机3a期试验,在20个国家和地区192个门诊和医院科室比较每周一次IcoSema与每周一次icodec在每日基础胰岛素治疗控制不佳的2型糖尿病成人中的疗效与安全性。第52周HbA1c自基线的估计平均变化IcoSema为-1.55个百分点,icodec为-0.89个百分点(估计治疗差异-0.66个百分点[95%CI -0.76至-0.57],p<0.0001)。IcoSema组临床显著或严重低血糖合并发生率显著低于icodec组(每人年暴露0.14 vs 0.63次;估计率比0.22[95%CI 0.14至0.36],p<0.0001)。
要点
- 每周一次IcoSema在降低HbA1c方面优于每周一次icodec单药(估计治疗差异-0.66个百分点,p<0.0001)。
- IcoSema组临床显著或严重低血糖合并发生率显著低于icodec组(估计率比0.22[95%CI 0.14至0.36])。
- 作者认为IcoSema可能为2型糖尿病成人胰岛素治疗强化提供一种选择。
核心结论
- 在每日基础胰岛素治疗控制不佳的2型糖尿病成人中,每周一次IcoSema在HbA1c变化和临床显著或严重低血糖合并发生率更低方面优于每周一次icodec单药。
- 作者认为IcoSema可能为2型糖尿病成人胰岛素治疗强化提供一种选择。
研究设计与样本
- COMBINE 1是一项52周、开放标签、达标治疗、随机、3a期试验,在20个国家和地区192个门诊和医院科室进行。
- 纳入18岁及以上、BMI≤40 kg/m2、HbA1c 7.0-10.0%(53.0-85.8 mmol/mol)、接受每日基础胰岛素联合或不联合口服降糖药的2型糖尿病患者,1:1随机分配至IcoSema(700 U/mL加2 mg/mL)或icodec(700 U/mL),均为皮下注射、每周同一天任意时间给药。
- 主要终点为基线至第52周HbA1c变化,在全分析集(所有随机分配参与者)中评估;试验注册号NCT05352815,已完成。
主要发现
- 2022年6月1日至2023年3月13日筛查1671人,1291人被随机分配至IcoSema(n=646)或icodec(n=645);平均年龄60.6岁(SD 10.3),男性799人(62%)、女性492人(38%)。
- 第52周HbA1c自基线8.22%(SD 0.83;66.3 mmol/mol[9.1])的估计平均变化:IcoSema组-1.55个百分点(SE 0.03;-16.9 mmol/mol[0.4]),icodec组-0.89个百分点(SE 0.03;-9.7 mmol/mol[0.4]);估计治疗差异-0.66个百分点(95%CI -0.76至-0.57;-7.3 mmol/mol[-8.3至-6.2];p<0.0001;优效性成立)。
- 基线至第57周临床显著或严重低血糖合并发生率IcoSema组低于icodec组(每人年暴露0.14 vs 0.63次;估计率比0.22[95%CI 0.14至0.36];p<0.0001;优效性成立)。
- 最常见不良事件:IcoSema组为胃肠系统疾病(644名参与者中303人[47%],试验期间共1033起事件);icodec组为感染和侵染(644名参与者中275人[43%],共466起事件)。
- 严重不良事件:IcoSema组59人(9%),icodec组69人(11%);无治疗相关死亡。
临床怎么用
- 作者认为IcoSema可能为2型糖尿病成人胰岛素治疗强化提供一种选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IcoSema is a once‑weekly combination therapy of basal insulin icodec (icodec) and semaglutide (a GLP‑1 analogue) currently in development. COMBINE 1 compared the efficacy and safety of IcoSema with once‑weekly icodec alone in adults with inadequately controlled type 2 diabetes on daily basal insulin therapy. METHODS: COMBINE 1, a 52‑week, open‑label, treat‑to‑target, randomised, phase 3a trial, was done at 192 outpatient clinics and hospital departments across 20 countries and regions. Individuals aged 18 years or older with a BMI of 40 kg/m2 or less and type 2 diabetes (HbA1c 7·0-10·0% [53·0-85·8 mmol/mol]) treated with daily basal insulin with or without oral glucose‑lowering medications were randomly assigned (1:1) via a randomisation and trial supply management system to IcoSema (700 U/mL plus 2 mg/mL) or icodec (700 U/mL), both administered as subcutaneous injections on the same day each week, at any time of the day. There was no stratification based on participants' baseline characteristics. The primary endpoint was change in HbA1c from baseline to week 52, evaluated in the full analysis set (all randomly assigned participants). The trial is registered with ClinicalTrials.gov, NCT05352815, and has been completed. FINDINGS: Between June 1, 2022, and March 13, 2023, 1671 individuals were screened, of whom 1291 (mean age 60·6 years [SD 10·3]; 799 [62%] males and 492 [38%] females) were randomly assigned to IcoSema (n=646) or icodec (n=645). At week 52, from a baseline value of 8·22% (SD 0·83; 66·3 mmol/mol [9·1]), estimated mean change in HbA1c was -1·55 percentage points (SE 0·03; -16·9 mmol/mol [0·4]) with IcoSema and -0·89 percentage points (SE 0·03]; -9·7 mmol/mol [0·4]) with icodec (estimated treatment difference [ETD] -0·66 percentages points [95% CI -0·76 to -0·57]; -7·3 mmol/mol [-8·3 to -6·2]; p<0·0001; superiority confirmed). The rate of combined clinically significant or severe hypoglycaemia from baseline to week 57 was significantly lower with IcoSema than with icodec (0·14 vs 0·63 episodes per person‑year of exposure; estimated rate ratio 0·22 [95% CI 0·14 to 0·36]; p<0·0001; superiority confirmed). The most frequently reported adverse events were within the system organ class of gastrointestinal disorders in the IcoSema group (303 [47%] of 644 participants had 1033 events during the trial) and infections and infestations in the icodec group (275 [43%] of 644 participants had 466 events. 59 (9%) participants in the IcoSema group and 69 (11%) participants in the icodec group had a serious adverse event. No treatment-related deaths occurred. INTERPRETATION: In adults with inadequately controlled type 2 diabetes on daily basal insulin therapy, once‑weekly IcoSema showed superiority to once-weekly icodec alone in changes in HbA1c and in overall lower rate of combined clinically significant or severe hypoglycaemia. IcoSema might provide an option for insulin therapy intensification in adults with type 2 diabetes. FUNDING: Novo Nordisk. TRANSLATIONS: For the Chinese and Japanese translations of the abstract see Supplementary Materials section.
引用
- Mathieu C, Giorgino F, Kim SG, et al. Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025. PMID: 40482671. doi:10.1016/S2213-8587(25)00096-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。